![]() |
Name |
6-Bromohexanoic acid, 4-hexadecyl ester
|
Molecular Formula | C22H43BrO2 | |
IUPAC Name* |
hexadecan-4-yl 6-bromohexanoate
|
|
SMILES |
CCCCCCCCCCCCC(CCC)OC(=O)CCCCCBr
|
|
InChI |
InChI=1S/C22H43BrO2/c1-3-5-6-7-8-9-10-11-12-14-18-21(17-4-2)25-22(24)19-15-13-16-20-23/h21H,3-20H2,1-2H3
|
|
InChIKey |
XXMUXYFPAPTIHD-UHFFFAOYSA-N
|
|
Synonyms |
6-Bromohexanoic acid, 4-hexadecyl ester; 1-Propyltridecyl 6-bromohexanoate #
|
|
CAS | NA | |
PubChem CID | 600960 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 419.5 | ALogp: | 9.3 |
HBD: | 0 | HBA: | 2 |
Rotatable Bonds: | 20 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 26.3 | Aromatic Rings: | 0 |
Heavy Atoms: | 25 | QED Weighted: | 0.116 |
Caco-2 Permeability: | -4.785 | MDCK Permeability: | 0.00001330 |
Pgp-inhibitor: | 0.004 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.903 |
30% Bioavailability (F30%): | 0.993 |
Blood-Brain-Barrier Penetration (BBB): | 0.045 | Plasma Protein Binding (PPB): | 96.75% |
Volume Distribution (VD): | 2.502 | Fu: | 1.60% |
CYP1A2-inhibitor: | 0.121 | CYP1A2-substrate: | 0.188 |
CYP2C19-inhibitor: | 0.279 | CYP2C19-substrate: | 0.06 |
CYP2C9-inhibitor: | 0.104 | CYP2C9-substrate: | 0.953 |
CYP2D6-inhibitor: | 0.526 | CYP2D6-substrate: | 0.079 |
CYP3A4-inhibitor: | 0.446 | CYP3A4-substrate: | 0.081 |
Clearance (CL): | 3.215 | Half-life (T1/2): | 0.143 |
hERG Blockers: | 0.306 | Human Hepatotoxicity (H-HT): | 0.186 |
Drug-inuced Liver Injury (DILI): | 0.51 | AMES Toxicity: | 0.029 |
Rat Oral Acute Toxicity: | 0.03 | Maximum Recommended Daily Dose: | 0.445 |
Skin Sensitization: | 0.962 | Carcinogencity: | 0.099 |
Eye Corrosion: | 0.911 | Eye Irritation: | 0.798 |
Respiratory Toxicity: | 0.936 |